Dr. Ghassan Abu Alfa, MD with Memorial Sloan Kettering Cancer Center in New York, provides an update on the key findings of the Himalaya clinical trial. The trial, a phase 3 study, investigated the combination of darvalumab and tremelumab for patients with intractable hepatocellular carcinoma. The study involved a phase 3 clinical trial, comparing the combination therapy to sorafenib, the prevailing standard care at that time and widely used globally. The primary focus was on enhancing survival outcomes with the combination of Dervalumab and Tremelumab versus Sorafenib. Notably, the median overall survival was approximately 16.5 months for the combination therapy…
Author: Editor
Dr. Jack West,MD an associate professor in medical oncology at City of Hope Comprehensive Cancer Center in Los Angeles, discussed a recent publication in the Annals of Oncology regarding the IMpower010 trial. The trial focused on the adjuvant use of atezolizumab and was initially presented by Dr. Heather Wakely and colleagues at ASCO 2021. The trial showed a statistically significant improvement in disease-free survival for patients with stage 2 to 3a resected non-small cell lung cancer and PD-L1 of 1% or higher who received adjuvant atezolizumab compared to placebo. While the trial demonstrated benefits in disease-free survival, further analysis reveals…
Naval Daver MD is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. Naval Daver, MD expresses uncertainty and discusses the need for personalized treatment strategies. He mentions starting with a metaphor about eggs and ice cream preferences. They highlight the lack of data on triple therapy and the importance of considering individual differences. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The talk shifts to triple…
Brian Andrew Jonas, M.D., Ph.D.- Hematology and Oncology – Hematology and Oncology – UC Davis Comprehensive Cancer Center The presentation discusses the management and treatment strategies for patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) receiving hypomethylating agents (HMA) in combination with venetoclax. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Brian Andrew Jonas, M.D., Ph.D. discusses various aspects of this treatment approach, including dosing regimens, response…
Jessica Altman, MD – Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine The presentation discusses various aspects of treatment strategies for newly diagnosed acute myeloid leukemia (AML), focusing on optimizing therapy approaches and providing practical insights for healthcare professionals. It delves into considerations for patients who are not suitable for intensive chemotherapy, explores the use of different approved or accessible agents, and emphasizes the importance of achieving transfusion independence and improved quality of life for AML patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open -…
In the dynamic world of oncology, chemotherapy stands as a beacon of hope for many battling the formidable challenge of cancer. When diagnosed with cancer, patients are presented with a spectrum of treatment modalities, and one of the most crucial decisions revolves around when and how to administer chemotherapy. Amidst the plethora of choices, one term has steadily gained prominence: neoadjuvant chemotherapy. But what is neoadjuvant chemotherapy? And how does it distinguish itself from other treatment strategies? What is Neoadjuvant Chemotherapy? Stepping into the world of oncology, terms and treatments can often feel overwhelming. Amidst the myriad of terminologies, neoadjuvant…
Courtney DiNardo, MD- Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Emerging as a beacon of hope in the realm of acute myeloid leukemia (AML) treatment, a new frontier is being forged through the synergistic power of innovative drug combinations. By intertwining the potency of IDH inhibitors like ivosidenib and enasidenib with hypomethylating agents and the precision of venetoclax, a novel therapeutic approach is taking center stage. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open…
Eytan M. Stein, MD – Hematologist-Oncologist – Memorial Sloan Kettering Cancer Center Discover the cutting-edge landscape of acute myeloid leukemia (AML) treatment with a focus on Revumenib and Ziftomenib, two promising menin inhibitors. Delving into the realm of AML therapy, this discussion navigates through the potential roles of Revumenib and Ziftomenib in treating relapsed and refractory cases, particularly among patients with KMT2A rearrangements and NPM1 mutations. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US…
Presented By: Brian Warnecke, DO – UC-Irvine Hematology Oncology Fellow, PGY-5 Date: August 12, 2023The presentation titled “Multi-omic Characterization of RCC1 Expression and its Association with Molecular Alterations, Immune Phenotypes, and Cancer Outcomes,” conducted by Brian Warnecke, D.O., a UC-Irvine Hematology Oncology Fellow in his PGY-5, unveils a comprehensive investigation into the multifaceted role of Regulator of Chromosome Condensation 1 (RCC1) in cancer development and progression. Collaboratively led by principal investigators Dr. Mohammed Al Hallak (Karmanos), Dr. Asfar Azmi (Karmanos), and Dr. Misako Nagasaka (UC Irvine), this research endeavor delves into the intricate interplay between RCC1 expression, molecular alterations, immune…
Presented By: Dalia Kaakour, MD – University of California, Irvine Date: Aug 12, 2023 In the realm of oncology and immunotherapy, the investigation into the safety and efficacy of immune checkpoint inhibitors (CPIs) takes a step forward with an insightful study by Dr. Dalia Kaakour, MD, MPH, from the University of California, Irvine’s Department of Medicine Division of Hematology and Oncology Fellowship Program. With an absence of any disclosures, this study delves into the realm of immune-related adverse events (irAEs) in patients afflicted by both solid tumors and advanced chronic kidney disease (CKD) who are undergoing treatment with CPIs. Traditionally,…
Presented By: Shirin Attarian, MD Date Aug 12, 2023 In the realm of oncology, Head and Neck Cancer stands as a significant challenge, both in terms of its prevalence and the intricacies surrounding its diagnosis and treatment. This complex and diverse set of malignancies affects millions across the globe each year, making it the seventh most common cancer worldwide. Amid the countless battles against this formidable adversary, the insights of medical professionals like Dr. Shirin Attarian have proven invaluable. Dr. Attarian’s meticulous review of Head and Neck Cancer reveals a landscape of statistics that underscore the urgency of continued research…
Alexander Edward Perl, MD, MS – Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania Alexander Edward Per, MD, MS emphasizes the need to unravel the intricacies of both primary and secondary resistance mechanisms associated with FLT3 inhibitors, highlighting their role in AML management. Discussions revolve around the potential of these inhibitors to target FLT3 mutations, while also addressing challenges such as polyclonality and the selection of resistant clones. The importance of achieving optimal disease response is underscored, with an emphasis on utilizing minimal residual disease (MRD) testing to guide treatment decisions and enhance patient outcomes. REGISTER…
Farhad Ravandi, MD is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. In his compelling presentation, Farhad Ravandi, MD, a distinguished medical professional in the field of oncology, delves into the critical significance of minimal residual disease (MRD) assessment in the realm of acute myeloid leukemia (AML) treatment. As an accomplished hematologist, Dr. Ravandi brings his extensive expertise to the forefront, elucidating how achieving complete morphological remission is a pivotal determinant in long-term survival for AML patients. REGISTER NOW…
Refresh URL Changing Content
Spotlight on Oncology: Exploring the Latest Advances in Lung Cancer Research Date: August 12, 2023 Speaker: Sai-Hong Ignatius Ou, MD PhD Welcome to the 2023 MAOSC Spotlight on Oncology, a dynamic event that brings together leading minds in the field of lung cancer research to discuss groundbreaking developments and insights. This year’s event focuses on the latest advancements in lung cancer treatment, with a special emphasis on the management of lung cancer through various stages. At the helm of this enlightening discussion is the esteemed Dr. Sai-Hong Ignatius Ou, MD PhD. Dr. Ou is a distinguished Health Science Clinical Professor…
teste desc
Updates in Lymphoma: Advancements in Treatment Strategies Date: August 12, 2023Presenter: Elizabeth Brem, MD (Clinical Associate Professor) In the ever-evolving landscape of oncology, particularly in the field of lymphoma treatment, significant strides have been made to improve patient outcomes and quality of life. Dr. Elizabeth Brem, a prominent figure in the field, delivered a comprehensive presentation on the recent updates in lymphoma treatment during the recent event. Dr. Brem is a Clinical Associate Professor renowned for her expertise and contributions to the field. Disclosures: Dr. Elizabeth Brem is associated with several pharmaceutical and biotech companies, reflecting her active engagement in…
Interview with Pankit Vachhani, MD Hematology Oncology- UAB Medicine Timestamps: 0:00:09 What is the objective of this study on indolent systemic mastocytosis (ISM)?0:00:50 How were patients with ISM randomized in this study, and what were the treatment groups?0:01:48 What was the primary endpoint measured in this study, and how was it assessed?0:02:20 What were the secondary endpoints evaluated in this study?0:03:19 What were the results regarding the mean change in total symptom score (TSS) between the avapritinib and placebo groups?0:04:17 How did avapritinib treatment impact serum tryptase levels in patients with ISM?0:05:02 Were there any notable differences in adverse events…
Amir T. Fathi MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital Join us on a journey to the forefront of Acute Myeloid Leukemia (AML) treatment, guided by the expertise of Amir T. Fathi MD. In the dynamic landscape of 2023, Dr. Fathi’s insights illuminate the remarkable progress being made, specifically within the realm of IDH 1/2-mutant AML cases. This transformative approach integrates cutting-edge molecular insights and targeted therapies, revolutionizing the trajectory of AML care. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL…
Harry Paul Erba, MD Professor of Medicine Member of the Duke Cancer Institute This content features Harry Paul Erba, MD, who discusses the optimization of frontline therapy for FLT3 mutated AML patients, focusing on quizartinib’s impact. Dr. Erba explains the pivotal role of FLT3 receptor tyrosine kinase in hematopoiesis and its connection to AML blast. He details the variations in FLT3 mutations, encompassing internal tandem duplication (ITD) and TKD mutations, elucidating their distinct prognostic implications. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU…
Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center. In a dynamic presentation at the recent event, Joseph D. Khoury, MD delved into the intricate realm of Acute Myeloid Leukemia (AML), shedding light on genetic advancements, diagnostic nuances, and promising targeted therapies. The engaging discourse began with gratitude for the invitation and San Diego’s delightful weather. Coming from varied backgrounds like Houston, Texas, and even Nebraska, the speaker emphasized their unique vantage point straddling different locales. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online…
The “MOASC SPOTLIGHT ON ONCOLOGY – GU ASCO UPDATES” seminar, led by Dr. Nataliya Mar, Clinical Associate Professor in the Division of Hematology/Oncology at the University of California Irvine, August 12, 2023 This discussion marked a significant milestone in the field of genitourinary oncology. Dr. Mar’s insightful presentation delved into various scenarios, revealing the complex landscape of oncology care and the advancements in treatment strategies. At the outset, Dr. Mar disclosed her affiliations with leading pharmaceutical companies, including Seattle Genetics, Aveo, Eisai, Tempus, and Merck, which underscores the relevance of her insights and findings in the context of emerging therapies…
Pancreatic Cancer Updates – Insights from Vincent Chung, MDDiscover the latest advancements in the field of pancreatic cancer through an enlightening presentation by Dr. Vincent Chung, a distinguished figure in oncology and a consultant for Perthera. Delve into the comprehensive exploration of Pancreatic Cancer, its challenges, and the transformative approaches to treatment. This event, held on August 12, 2023, at the MOASC / UCI Spotlight on Oncology, presents crucial updates that could revolutionize the landscape of pancreatic cancer care.Understanding the Scope of the ProblemWith the unfortunate distinction of having the worst survival rates among solid tumors, pancreatic cancer poses a…
Anthony El-Khoueiry, MD. As the Associate Director for Clinical Research and Phase 1 Program Director at the prestigious USC Norris Comprehensive Cancer Center Discover the latest advancements in the field of Hepatobiliary Cancers in this comprehensive session titled “Hepatobiliary Cancers Therapeutic Updates” featuring the esteemed Anthony El-Khoueiry, MD. As the Associate Director for Clinical Research and Phase 1 Program Director at the prestigious USC Norris Comprehensive Cancer Center, Dr. El-Khoueiry brings his expertise to illuminate the cutting-edge developments in the treatment of hepatobiliary cancers.This session delves into critical topics that are reshaping the landscape of hepatobiliary cancer therapies. The intricate…
MOASC – Spotlight on Oncology Colorectal Cancer AbstractsDate: August 12, 2023Location: Huntington Beach, CAPresenter: Jason A. Zell, DO, MPHPosition: Professor, Vice Chief of Academic AffairsDivision of Hematology/Oncology, Dept. of MedicineUniversity of California Irvine In this spotlight session on oncology, the focus was on Colorectal Cancer (CRC) abstracts, with special attention given to the latest advancements and research findings. The presenter, Dr. Jason A. Zell, a distinguished figure in the field, holds the position of Professor and Vice Chief of Academic Affairs within the Division of Hematology/Oncology at the University of California Irvine. Abstracts were presented, shedding light on significant studies…
Dr. Sayeh Lavasani, MD, MSc, FRCPC, an Associate Clinical Professor in the Division of Hematology Oncology at the Department of Medicine, UCI Health, presented updates on breast cancer research during the MOASC (Medical Oncology Association of Southern California) Spotlight On Oncology. Here’s a breakdown of the key topics discussed: Presenter Disclosures: Dr. Lavasani’s disclosures include associations with Daichii Sankyo, Seagen, Sermonix, and Astrazeneca for honorarium, institutional research funding, consultation, and speaker engagements. Outline: Hormone Positive Breast Cancer: Early Stage (NATALEE) Metastatic Breast Cancer: SONIA HER2+ Breast Cancer: PHERGain (Cortes et al.) Key Highlights: Hormone Positive Breast Cancer – NATALEE Study:…
In the ever-evolving world of oncology, there is always a beacon of hope on the horizon. The latest such promise comes in the form of a drug known as Sacituzumab Govitecan. This compound, while complex in name, is pioneering some of the latest advancements in cancer treatments, particularly in the realm of Triple-Negative Breast Cancer (TNBC). What is Sacituzumab Govitecan? Every drug, from the over-the-counter solutions to groundbreaking cancer treatments, has a story to tell, often starting with its name. Sacituzumab Govitecan isn’t merely a jumble of syllables. It’s a name derived from the drug’s intricate nature and function. While…
Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Sanam Loghavi is an accomplished pathologist known for her expertise in the field of hematopathology and her contributions to the diagnosis and understanding of various hematologic malignancies, including acute myeloid leukemia (AML). Her work focuses on unraveling the molecular intricacies of AML and other blood disorders to enhance patient care through personalized treatment strategies. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open -…
For those with an interest in the management of acute myeloid leukemia, the conference provided a unique and valuable platform. Attendees commended the insightful talks and the lively debates that ensued, offering a wealth of perspectives and research ideas. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The sentiment expressed was overwhelmingly positive, with participants applauding the conference’s exceptional speakers, engaged audience, interactive format, and the prospect of forging new…
The discussion revolves around the complexities of Blinatumomab treatment for leukemia, with experts debating the reasons behind the partial clinical hold on cooperative group studies, concerns about combining treatments concurrently, and the potential impact of reducing chemotherapy intensity. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Topics also include the risk of CNS relapses, the significance of IT chemotherapy, and the emergence of CD19-negative relapses with Blinatumomab. The experts emphasize…
The panel discussed various aspects related to the use of next-generation sequencing (NGS) and flow cytometry for minimal residual disease (MRD) detection in patients with various types of leukemia, particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). They touched upon the challenges and benefits of using NGS for detecting MRD at greater detection depths. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The question arose as to whether…
In this lively debate, experts engage in a comprehensive analysis of Nelarabine’s efficacy in the treatment of ALL. The discussion covers its benefits and drawbacks, particularly focusing on its usage in EFS and DFS within the pivotal trial. Controversial points emerge regarding its impact on survival rates, with contrasting viewpoints on its effectiveness in pediatric and adult populations. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The potential of combination…
In a dynamic and insightful debate, leading experts in the field of leukemia treatment delved into the intricacies of optimizing therapies for relapsed acute lymphoblastic leukemia (ALL). The discussion revolved around cost-effective strategies and clinical considerations for achieving enhanced outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The experts examined the potential of combining various treatments, including CAR T-cell therapy, to mitigate the escalating costs of managing relapsed ALL.…
We mourn the profound loss of Dr. Krystal Cascetta, a committed oncologist and breast cancer researcher. Our hearts extend to her family, friends, patients, and colleagues in these challenging times. In memory of her life and contributions, we highlight the severe mental health challenges faced by oncology professionals. Managing gravely ill patients, navigating intricate diseases, and daily confrontations with mortality exert a heavy emotional burden. Oncologists face higher rates of burnout, depression, and suicide compared to other physicians. It’s crucial that we foster a culture in oncology that forefronts mental health and well-being. Dr. Cascetta was not only a compassionate…
The panel discussion centered on the optimization of leukemia treatment, particularly focusing on the combination of venetoclax with various therapies. Preclinical data and pathophysiology were explored, highlighting the potential of inhibiting JAK2 mutations with venetoclax. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Concerns were raised about CNS relapse and CD19-negative relapses, emphasizing the need for continued IT chemotherapy. The balance between systemic chemotherapy reduction and comprehensive coverage with antigen-directed…
When discussing the myriad of cancers that affect humans, head and neck cancers, though slightly less talked about, remain a significant concern for medical professionals and patients alike. These cancers, which can originate in the oral cavity, throat, larynx, paranasal sinuses, and nasal cavity, are often diagnosed late due to their subtle initial symptoms. As a result, the need for effective treatments is palpable, especially for those cases where the disease has metastasized or recurred after initial treatment. Over the years, there’s been a growing interest in leveraging the body’s immune system to combat cancers, a treatment approach referred to…
The discussion centered on optimizing leukemia treatment strategies through the combination of immunotherapies and chemotherapy. The concern of CNS relapse and CD19-negative relapses was highlighted, emphasizing the importance of continued IT chemotherapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com While there is interest in reducing systemic chemotherapy, caution was advised due to potential resistance. The potential of combining antigen-directed therapies with chemotherapy for better coverage was discussed, along with…
This in-depth discussion among experts explores various facets of leukemia management. The conversation spans topics including challenges in clonotypable patients, the significance of MRD negativity in high-risk genetics, and the ongoing debate surrounding the necessity of transplantation for specific patient groups. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The experts also touch on practical considerations, such as the frequency of peripheral blood monitoring compared to bone marrow assessments.
Medical experts engaged in a discussion about advancing pediatric acute myeloid leukemia (AML) treatment strategies. Venetoclax, a promising drug, was a focal point, and its potential inclusion in pediatric protocols was explored. The challenge of adapting adult regimens to pediatric patients while considering drug forms suitable for children was discussed. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The importance of collaborative trials, merging efforts across pediatric and adult AML,…
Navigating the ever-evolving landscape of leukemia treatment has become an intricate endeavor, with recent clinical trials offering intriguing insights and sparking lively debates. These trials delve into the effectiveness of innovative therapies such as gilteritinib and midostaurin, potentially reshaping the foundation of standard care protocols. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Controversies emerge surrounding the significance of randomized studies in a rapidly changing environment, where salvage therapies like…
The conversation focuses on AML treatments, including arsenic and another frontline approach. Preventing relapses through non-toxic drugs like masitinib is explored. Financial obstacles and customized treatments are discussed. The importance of precise timing for treatments is highlighted. Myelosuppression and new dosing ideas are brought up. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Clinical trial design’s role in optimizing treatment is mentioned, with examples of challenges in drug approval. The need…
In this discussion, the focus is on optimizing Acute Myeloid Leukemia (AML) treatment. The idea of reducing drug doses upon achieving remission is challenged, questioning its efficacy against resistant disease. The notion of increasing drug doses to target resistance for improved outcomes is proposed. Perspectives diverge, with one side highlighting the need for conservative dosing to manage toxicities, while the other suggests early, aggressive intervention. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus…
Leading experts engage in a comprehensive discussion on the intricate landscape of long-term remission and resistance patterns in transplanted acute myeloid leukemia (AML) patients, focusing on the potential role of Menin Inhibitor maintenance therapy. The dialogue delves into post-transplant outcomes and the emergence of resistance mutations, referencing previous presentations at the American Society of Hematology (ASH) meeting. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Central topics include the distinction…
Ryan Fitzpatrick, CEO, MD Education In opening the Focus Meeting 2023, Ryan Fitzpatrick, CEO, expresses gratitude to attendees and collaborators for their efforts. The importance of gathered speakers is emphasized, promising insightful discussions. Professional conduct and the value of fellows and junior faculty members are underscored. Logistical details, including breaks and a dinner, are outlined. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Online resources’ availability is noted, extending the…
The discussion revolves around complex topics related to acute myeloid leukemia (AML), including its groups, molecular markers, patient eligibility for clinical trials, and considerations of germline predisposition. Participants delve into the challenges of defining AML subtypes, the significance of molecular markers in diagnosis and treatment decisions, and the potential impact of germline factors on patient outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The conversation also touches on the…
In the ever-evolving landscape of medical science, melanoma and Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) have remained two of the most formidable cancers to treat. Both of these cancers present unique challenges due to their aggressive nature and high recurrence rate. Yet, in the shadow of these challenges, targeted therapies have emerged as a beacon of hope. Targeted therapies are a relatively new addition to the oncological toolkit. Unlike traditional treatments that indiscriminately target both healthy and cancerous cells, targeted therapies focus precisely on the specific genes and proteins that are involved in the growth…
Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center. Joseph Corey, MD, Chair of Pathology and Microbiology at the University of Nebraska Medical Center, Omaha, presented a seminar on acute myeloid leukemia (AML) classification and its genetic underpinnings. The conference offered a platform for AML physicians and diagnostic specialists, like Corey, to exchange insights. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus…
Harry Paul Erba, MD Professor of Medicine and Member of the Duke Cancer Institute Harry Erba, MD, a respected Duke University Medicine Professor, refines intensive chemotherapy for FLT3 mutated AML patients. He validates Midostaurin’s potential via the RATIFY trial and now focuses on potent second-gen FLT3 inhibitors. In the quantum first study, quizartinib enhances ITD mutated AML survival, particularly in younger patients (hazard ratio 0.68). Older patients also benefit, though less significantly (hazard ratio 0.9). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU…